Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Thanks for this - I never would have read through

Message Board Public Reply | Private Reply | Keep | Replies (3)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155054
(Total Views: 710)
Posted On: 02/23/2021 12:55:27 AM
Posted By: Borel Fields
Re: MD VIROLOGIST #79402
Thanks for this - I never would have read through to page 10 myself to find the FDA's new recommendations on efficacy outcome definition.

Do you have any idea why the FDA would prefer a longer outcome period for critical than "non-critical" cases - 60 vs. 28 days? Are they describing a different clinical course?

Outside of follow-up period, we match this document's 5 categories pretty well: We have mortality and can compute "alive and non-ventilated." Their third bullet is precisely our "7-point ordinal scale." Their fourth bullet isn't our S.O.F.A. score, but it is based on "first occurrence" or various thromboses, with stroke and heart failure added in. We probably have the extra data. Their point 5, "time to recovery" doesn't seem relevant.

I'm wondering if the FDA under somewhat-iconoclastic Woodcock is asking for data directly so they can create apples-to-apples comparisons of various trials. To hell with stated endpoints!

I'm not too worried about not having 60 day data in this case - censored data techniques (Cox model) uses 60 day data on all patients that have it, 42-day data on those with only that much, etc.

I'm very interested in the clinical meaning of wanting a longer follow-up for critical patients. Ideas?


(8)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us